[FOLFOX和FOLFIRI方案用于结直肠癌肝转移新辅助化疗的结果]

[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].

作者信息

Amano Ryosuke, Yamada Nobuya, Noda Eiji, Kubo Naoshi, Tanaka Hiroaki, Muguruma Kazuya, Inoue Toru, Yashiro Masakazu, Maeda Kiyoshi, Onoda Naoyoshi, Sawada Tetsuji, Nakata Bunzo, Ohira Masaichi, Ishikawa Tetsuro, Hirakawa Kosei

机构信息

Department of Surgical Oncology, Osaka City University Graduate School of Medicine.

出版信息

Gan To Kagaku Ryoho. 2009 Nov;36(12):2003-5.

PMID:20037305

Abstract

We analyzed a treatment outcome and the effect of FOLFOX and FOLFIRI neo-adjuvant chemotherapy (NAC) for patient with liver metastasis of colorectal cancer. Eleven patients undergoing hepatectomy after NAC were investigated. FOLFOX was performed for 8 patients, and FOLFIRI was for 3 patients. The response rate was 45.5% (PR 5, SD 6), and the reduction rate was 37.7%. The average ICG R15 value before hepatectomy was 13.7%. A complication during and after operations was not recognized. The average observation period was 19.8 months (8-45 months). Now, 9 patients are alive with no recurrence. NAC by FOLFOX for liver metastasis of colorectal cancer showed a high reduction rate, and there was a little influence to hepatectomy indicating that FOLFOX could be an effective therapy.

摘要

我们分析了FOLFOX和FOLFIRI新辅助化疗（NAC）对结直肠癌肝转移患者的治疗效果。对11例接受NAC后行肝切除术的患者进行了研究。8例患者接受FOLFOX方案，3例患者接受FOLFIRI方案。缓解率为45.5%（PR 5例，SD 6例），缩小率为37.7%。肝切除术前平均吲哚菁绿滞留率（ICG R15）值为13.7%。术中及术后未发现并发症。平均观察期为19.8个月（8 - 45个月）。目前，9例患者存活且无复发。FOLFOX方案的NAC对结直肠癌肝转移显示出较高的缩小率，对肝切除术影响较小，表明FOLFOX可能是一种有效的治疗方法。